alitretinoin
Also known as 9-cis-retinoic acid, Panretin®, Toctino®, Panrexin, (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, 9-cis-Tretinoin, 9(Z)-Retinoic acid, (7E,9Z,11E,13E)-retinoic acid
Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. It is a first generation retinoid. Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.
Research
929 papers- Alitretinoin.American journal of clinical dermatology · 2000
- Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.Lancet (London, England) · 2025
- Alitretinoin for the treatment of severe chronic eczema of the hands.Expert opinion on pharmacotherapy · 2022
- Alitretinoin: a comprehensive review.Expert opinion on investigational drugs · 2008
- Alitretinoin as a Treatment Modality for Ichthyosis in Women of Childbearing Age: A Case Series and Review of the Literature.Dermatology (Basel, Switzerland) · 2024
via PubMed
Article
16 sectionsContents
- Medical uses
- Kaposi's sarcoma
- Chronic hand eczema
- Interactions with other medications
- Adverse effects
- Systemic use
- Topical use
- Contraindications
- Interactions
- Overdose
- Pharmacological properties
- Mechanism of action
- Absorption and distribution in the body
- Synthesis
- References
- External links
Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. It is a first generation retinoid. Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.
==Medical uses==